Fund Overview

  • Ticker:
    FBT
  • Fund Category:
    Sector Equity
  • Fund Manager:
    FT Portfolios Canada Co.
  • Portfolio Advisor:
    First Trust Advisors L.P.
  • CUSIP:
    33742D105
  • ISIN:
    CA33742D1050
  • SEDOL:
    BMFNCT0
  • Currency:
    CAD
  • Fiscal Year-End:
    31-12
  • Exchange:
    Toronto Stock Exchange
  • Inception:
    2014-10-29
  • Inception Price:
    $19.63
  • Inception NAV:
    $19.63
  • Eligibility:
    RRSP, RRIF, RESP, TFSA, DPSP, RDSP

Fees and Expenses

  • Management Fee: 0.15%
  • MER: 0.80% as at 2020-12-31
The First Trust ETF's management fee changed from 0.70% per annum of net asset value to 0.15% per annum of net asset value and will bear the net operating expenses of the underlying fund (i.e. First Trust NYSE Arca Biotechnology Index Fund) which is 0.55% per annum of net asset value. Effective February 17, 2021.
Please refer to the prospectus for detailed explanation of the funds fees and expense.

Distribution Information (as at 2021-09-20)

  • Dividend Frequency:
    Quarterly

Fund Characteristics (as at 2021-08-31)2

  • Maximum Market Cap.:
    $192,216
  • Median Market Cap.:
    $20,436
  • Minimum Market Cap.:
    $1,362
  • Price/Book:
    4.97
  • Price/Cash Flow:
    16.14
  • Price/Sales:
    7.10
In February 2021, the First Trust AlphaDEX™ U.S. Materials Sector Index ETF (the "First Trust ETF") changed its investment objectives to seek to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE Arca Biotechnology IndexSM. In connection with the change of investment objectives, the name of the First Trust ETF changed to First Trust NYSE Arca Biotechnology ETF. The First Trust ETF provides exposure to its new index by investing all or substantially all of its assets in an underlying U.S. index fund known as First Trust NYSE Arca Biotechnology Index Fund, which is managed by the First Trust ETF's portfolio advisor. The effective date of change is February 17, 2021.

Investment Objective

First Trust NYSE Arca Biotechnology ETF (the "First Trust ETF") seeks to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE Arca Biotechnology IndexSM.

Current Data (as at 2021-09-20) Currency: CAD

NAV1% Change$ Change
$30.01-1.08%-$0.33
Daily Volume52-Week High/LowAVG 30-Day Volume
195$31.48 / $22.91101
Total Net AssetsOutstanding UnitsNumber of Holdings
$900,25330,0001

Top Holding (as at 2021-09-20)3

Holding % of Net Assets
First Trust NYSE Arca Biotechnology Index Fund 99.93%

Portfolio Composition (as at 2021-09-20)3

Industry % of Net Assets
Pharmaceuticals and Biotechnology 65.70%
Other 23.46%
Medical Equipment and Services 7.42%
Health Care Providers 3.29%
Cash & Equivalents 0.13%

Country Breakdown (as at 2021-09-20)3

Country % of Net Assets
United States 84.28%
Germany 4.71%
Ireland 4.02%
The Netherlands 3.72%
Spain 3.16%

Risk Rating

This rating is based on how much the ETF’s returns have changed from year to year. It doesn’t tell you how volatile the ETF will be in the future. The rating can change over time. An ETF with a low risk rating can still lose money.

For more information about the risk rating and specific risks that can affect the ETF’s returns, see the Risk section of the ETF’s prospectus.

Footnotes

1 The NAV represents the fund's net assets (assets less liabilities) divided by the fund's outstanding shares .
2 All market capitalization numbers are in CAD$ Millions.
3 Percentage of net assets may not equal 100%

Commissions, trailing commissions, management fees and expenses all may be associated with Exchange-Traded Fund investments. Please carefully read the prospectus of the fund before investing. Exchange-Traded funds are not guaranteed, their values change frequently and past performance may not be repeated.